Physician profile
Philip Schauer
NPI 1952494262
$93,951.82
in general payments reported to CMS, 2019-2025
26 companies · $4,482 in 2025
The $4,482 reported for 2025 was more than what 89% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $5,452 · 2021: $7,807 · 2022: $30K · 2023: $8,491 · 2024: $36K · 2025: $4,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Food and Beverage: $4,757 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,400 · Travel and Lodging: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,526.50 |
| Food and Beverage | $4,757.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,400.00 |
| Travel and Lodging | $2,309.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $32,997.81 | 2020-2025 | Echelon Flex, Harmonic |
| Novo Nordisk INC | $12,893.14 | 2021-2025 | Wegovy, Saxenda |
| Regeneron Pharmaceuticals, INC. | $12,606.27 | 2024 | |
| Ethicon US, LLC | $11,781.46 | 2019-2025 | Echelon Flex, Harmonic, Linx Reflux Management System |
| Eli Lilly and Company | $6,775.44 | 2024 | Zepbound |
| Medtronic, INC. | $5,064.53 | 2021-2025 | Signia, Ligasure, Sonicision |
| Heron Therapeutics, INC. | $4,522.11 | 2022-2023 | Zynrelef |
| Ethicon INC. | $2,343.75 | 2019-2025 | N/A |
| Covidien LP | $2,284.24 | 2019-2020 | |
| Intuitive Surgical, INC. | $716.48 | 2022 | |
| W. L. Gore & Associates, INC. | $375.81 | 2019-2025 | Gore Enform Preperitoneal Biomaterial, Gore Synecor Biomaterial |
| Conmed Corporation | $267.53 | 2019 | |
| Davol INC. | $265.28 | 2019-2021 | |
| Integra Lifesciences Corporation | $232.84 | 2021-2022 | |
| Lilly USA, LLC | $217.37 | 2024-2025 | Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $163.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.46 | 2025 | |
| Stryker Corporation | $98.71 | 2019 | |
| Next Science LLC | $82.50 | 2020 | |
| Intra-Sana Laboratories | $36.56 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Rhythm Pharmaceuticals, INC. | $27.52 | 2023 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $25.35 | 2023 | Gattex |
| Eagle Pharmaceuticals, INC. | $20.49 | 2023 | |
| Currax Pharmaceuticals LLC | $16.35 | 2025 | Contrave |
| Endo Pharmaceuticals INC. | $14.13 | 2023 | Nascobal |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Schauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.